Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Diabetes"
DOI: 10.4239/wjd.v13.i12.1168
Abstract: BACKGROUND Cardiovascular outcome trials have demonstrated cardiovascular safety of glimepiride (a sulfonylureas) against dipeptidyl peptidase-4 inhibitor linagliptin. Gliclazide (another newer sulfonylureas) has shown similar glycemic efficacy and 50% decreased risk of hypoglycemia compared to glimepiride.… read more here.
Keywords: gliclazide linagliptin; systematic review; risk; gliclazide ... See more keywords